Laurus Labs Limited (NSE:LAURUSLABS)
830.20
-2.10 (-0.25%)
Sep 29, 2025, 9:30 AM IST
Laurus Labs Revenue
Laurus Labs had revenue of 15.70B INR in the quarter ending June 30, 2025, with 31.35% growth. This brings the company's revenue in the last twelve months to 59.29B, up 17.31% year-over-year. In the fiscal year ending March 31, 2025, Laurus Labs had annual revenue of 55.54B with 10.18% growth.
Revenue (ttm)
59.29B
Revenue Growth
+17.31%
P/S Ratio
7.58
Revenue / Employee
9.61M
Employees
6,167
Market Cap
449.30B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 55.54B | 5.13B | 10.18% |
Mar 31, 2024 | 50.41B | -10.00B | -16.55% |
Mar 31, 2023 | 60.41B | 11.05B | 22.39% |
Mar 31, 2022 | 49.36B | 1.22B | 2.54% |
Mar 31, 2021 | 48.14B | 19.82B | 69.99% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Laurus Labs News
- 13 days ago - Divi’s Lab and Laurus Labs in focus as August export data signals strong growth - Business Upturn
- 5 weeks ago - Laurus Labs to dissolve CDMO arm Laurus Synthetics as part of rejig - The Times of India
- 2 months ago - Why are Laurus Labs shares up over 2% today? Explained - Business Upturn
- 2 months ago - Stocks to watch on brokerages, July 28: Mphasis, Cipla, Kotak Bank, Laurus Labs, IDFC First Bank, Bank of Baorda, SBI Cards, and more in focus - Business Upturn
- 2 months ago - Antique maintains hold on Laurus Labs, raises target to Rs 700 as CDMO momentum persists but visibility stays limited - Business Upturn
- 2 months ago - Motilal Oswal maintains buy on Laurus Labs, raises target to Rs 970 on strong CDMO-led earnings momentum - Business Upturn
- 2 months ago - Kotak Institutional Equities maintains sell on Laurus Labs, raises target to Rs 555 as earnings recovery seen priced in - Business Upturn
- 2 months ago - Jefferies maintains underperform on Laurus Labs, raises target to Rs 590 as margin concerns persist despite Q1 beat - Business Upturn